About Us
Company Information
Company Profile
- Company Name
- iXgene Inc.
- Address
- 1-6 Naito-cho, Shinjuku-ku, Tokyo
- Establishment
- January 6, 2020
- Capital
- 90 million yen
- Representative Director
- Dr. Toshiharu Furukawa
- Main Business
- Development of regenerative medicine using genome-edited iPS cells
- Access
Our History
- November 2018
- Basic patent application PCT/JP2018/042629 “Suicide gene therapeutic agent for brain tumors using pluripotent stem cell.”
- January 2020
- Establishment of iXgene
- March 2020
- Publication on gene-cell therapy for glioblastoma using suicide gene-transfected iPS cell-derived neural stem cells R. Tamura, Hum. Gene Ther.(2020)
- October 2020
- Seed round financing completed
- March 2021
- Patent application PCT/JP2021/13834 ”Therapeutic agent using genome-edited pluripotent stem cell”
- December 2022
- Series A financing completed
- June 2023
- Publication on neuroprotective effects of genome-edited iPS cell-derived neural stem cells in traumatic brain injury R. Imai, Stem Cells (2023)
- August 2023
- Signed a three-way joint research agreement with Sumitomo Pharma and Keio University.